Bolt Biotherapeutics Faces Nasdaq Delisting
Ticker: BOLT · Form: 8-K · Filed: Jul 3, 2024 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, sec-filing
TL;DR
Bolt Bio is getting kicked off Nasdaq, looking at options.
AI Summary
Bolt Biotherapeutics, Inc. filed an 8-K on July 3, 2024, to report that it has failed to meet the continued listing standards of the Nasdaq Stock Market. The company is currently evaluating its options regarding the delisting.
Why It Matters
This filing indicates a significant financial or operational challenge for Bolt Biotherapeutics, potentially impacting its stock value and ability to raise capital.
Risk Assessment
Risk Level: high — Failure to meet listing standards suggests severe financial distress or operational issues, posing a high risk to investors.
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Listing Exchange
- July 3, 2024 (date) — Filing Date
- July 2, 2024 (date) — Earliest Event Reported Date
FAQ
What specific continued listing rule did Bolt Biotherapeutics fail to satisfy?
The filing states that Bolt Biotherapeutics failed to satisfy a continued listing rule or standard of the Nasdaq Stock Market, but does not specify which rule in this section.
What are Bolt Biotherapeutics' options regarding the delisting?
The filing indicates that the company is currently evaluating its options regarding the delisting.
When was this 8-K form filed?
This 8-K form was filed on July 3, 2024.
What is the principal executive office address for Bolt Biotherapeutics?
The principal executive offices are located at 900 Chesapeake Drive, Redwood City, California, 94063.
Has Bolt Biotherapeutics changed its name or address recently?
The filing notes 'Not Applicable' for former name or former address, if changed since last report, implying no recent changes.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2024-07-03 17:19:30
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Global Se
- $1.00 — nsecutive trading days had fallen below $1.00 per share, which is the minimum average
Filing Documents
- d796654d8k.htm (8-K) — 24KB
- 0001193125-24-175113.txt ( ) — 144KB
- bolt-20240702.xsd (EX-101.SCH) — 3KB
- bolt-20240702_lab.xml (EX-101.LAB) — 18KB
- bolt-20240702_pre.xml (EX-101.PRE) — 11KB
- d796654d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Bolt Biotherapeutics, Inc. Date: July 3, 2024 By: /s/ William P. Quinn William P. Quinn President, Chief Executive Officer and Chief Financial Officer